Capricor Therapeutics (CAPR) Stock Analysis Report

General Information

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs.

The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Capricor Therapeutics (CAPR) Stock Graph

How We Grade Capricor Therapeutics (CAPR)

We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.

The chart below shows how we grade Capricor Therapeutics (CAPR) across the board compared to its closest peers.

Benzinga Edge Rankings

Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.

92.06

Momentum measures a stock's relative strength based on its price movement patterns and volatility over multiple timeframes, ranked as a percentile against other stocks.

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Past Performance

How has Capricor Therapeutics (CAPR) performed over the past 5 years?

The two main factors that we consider when analyzing past performance is overall return and volatility

Using these two metrics, we can determine if this stock gave its investors enough return for the risk that they took on by owning it. This is measured by the sharpe ratio, which has been used as a primary measure of risk/reward trade-off for almost 60 years.

This ratio can be interpreted as the amount of return an investor has received for the amount of risk that they took on by owning the stock over that timeframe.

Capricor Therapeutics (CAPR) sharpe ratio over the past 5 years is 0.4962 which is considered to be above average compared to the peer average of -0.2671

Analyzing Capricor Therapeutics (CAPR) Recent Options Activity

Below, you can see the trend in options sentiment over the past 30 days.

Based on our data, CAPR's options trades have recently carried more negative sentiment than positive.

Company Financials

INCOME STATEMENT

The income statement also known as the profit and loss statement, primarily focuses on the company's revenues and expenses during a particular period.

The main purpose of an income statement is to convey details of profitability and business activities. Below, is CAPR's income statement for the previous four years along with its trailing-twelve- month profit & loss.

FISCAL YEAR (BIL.)

2022 ($)

2023 ($)

2024 ($)

2025 ($)

TTM ($)

Total Revenue

0.00

0.03

0.02

0.00

Operating Revenue

0.00

0.03

0.02

0.00

Cost Of Revenue

—

Gross Profit

—

Operating Expense

0.03

0.05

0.06

0.11

0.12

Selling General And Administration

0.01

0.02

0.03

Research and Development

0.02

0.04

0.05

0.08

0.09

Operating Income

-0.03

-0.02

-0.04

-0.11

-0.12

Net Non-Operating Interest Income Expense

—

Other Income Expense

0.00

0.01

Other Non-Operating Income Expenses

—

0.00

Pre-Tax Income

-0.03

-0.02

-0.04

-0.11

Tax Provision

—

Net Income

-0.03

-0.02

-0.04

-0.11

Net Income Common Stockholders

-0.03

-0.02

-0.04

-0.11

Total Operating Income As Reported

-0.03

-0.02

-0.04

-0.11

-0.12

Total Expenses

0.03

0.05

0.06

0.11

0.12

Net Income From Continuing And Discontinued Operation

-0.03

-0.02

-0.04

-0.11

Normalized Income

-0.03

-0.02

-0.04

-0.11

-0.12

Interest Income

—

Interest Expense

—

Net Interest Income

—

EBIT

-0.03

-0.02

-0.04

-0.10

-0.11

EBITDA

-0.03

-0.02

-0.04

-0.10

-0.11

Reconciled Cost Of Revenue

—

Reconciled Depreciation

0.00

Normalized EBITDA

-0.03

-0.02

-0.04

-0.11

-0.12

Tax Rate For Calcs

0.00

Tax Effect Of Unusual Items

0.00

BALANCE SHEET

The balance sheet is a snapshot of a companies financials during a particular period in time.

It breaks down what company owns (assets) and what a company owes (liabilities), in order to give investors an overview of its capital structure.

FISCAL YEAR (BIL.)

2022 ($)

2023 ($)

2024 ($)

2025 ($)

TTM ($)

Total Assets

0.05

0.06

0.17

0.36

0.33

Current Assets

0.04

0.05

0.16

0.32

0.28

Total Non-Current Assets

0.01

0.03

0.04

Total Liabilities Net Minority Interest

0.04

0.03

0.05

Current Liabilities

0.02

0.03

0.02

0.04

0.03

Other Non-Current Liabilities

0.00

—

Total Equity Gross Minority Interest

0.01

0.02

0.15

0.31

0.28

Stockholders Equity

—

Total Capitalization

0.01

0.02

0.15

0.31

0.28

Common Stock Equity

0.01

0.02

0.15

0.31

0.28

Net Tangible Assets

0.01

0.02

0.15

0.31

0.28

Working Capital

0.02

0.14

0.29

0.25

Invested Capital

0.01

0.02

0.15

0.31

0.28

Tangible Book Value

0.01

0.02

0.15

0.31

0.28

Total Debt

0.00

0.01

Net Debt

—

Share Issued

0.03

0.05

0.06

Ordinary Shares Number

0.03

0.05

0.06

CASH FLOW STATEMENTS

A companies statement of cash flows gives an investor a break down of the cash inflows and outflows from a companies operations and investment activities.

FISCAL YEAR (BIL.)

2022 ($)

2023 ($)

2024 ($)

2025 ($)

TTM ($)

Cash Flow from Continuing Operating Activities

0.00

-0.03

-0.04

-0.07

-0.09

Net Income from Continuing Operations

-0.03

-0.02

-0.04

-0.11

Depreciation and Amortization

0.00

Deferred Tax

—

Deferred Income Tax

—

Stock-Based Compensation

0.00

0.01

0.02

Other Non-Cash Items

0.00

Change in Working Capital

0.03

-0.01

0.01

0.00

Change in Receivables

0.00

-0.01

0.00

0.01

0.00

Changes in Account Receivables

—

Change in Inventory

—

Change in Payables and Accrued Expense

0.00

0.01

0.00

Change in Payable

—

Change in Account Payable

—

Change in Other Current Assets

—

Change in Other Current Liabilities

—

Change in Other Working Capital

0.03

0.00

-0.01

—

Cash Flow from Continuing Investing Activities

-0.04

0.01

-0.12

0.10

-0.08

Net PPE Purchase and Sale

0.00

-0.01

-0.02

Net Business Purchase and Sale

—

Purchase of Business

—

Net Investment Purchase and Sale

—

0.01

-0.11

0.11

-0.06

Purchase of Investment

—

-0.10

-0.21

-0.15

-0.31

Sale of Investment

—

0.10

0.09

0.26

0.25

Net Other Investing Changes

—

Financing Cash Flow

0.00

0.03

0.15

0.25

Cash Flow from Continuing Financing Activities

0.00

0.03

0.15

0.25

Net Issuance Payments of Debt

—

Net Long-Term Debt Issuance

—

Long-Term Debt Issuance

—

Long-Term Debt Payments

—

Net Short-Term Debt Issuance

—

Net Common Stock Issuance

0.00

—

0.15

0.24

—

Common Stock Issuance

0.00

—

0.15

0.24

—

Common Stock Payments

—

Cash Dividends Paid

—

Net Other Financing Charges

—

End Cash Position

0.09

0.04

0.10

0.36

0.44

Changes in Cash

-0.03

0.01

0.00

0.28

0.08

Beginning Cash Position

0.12

0.04

0.10

0.08

0.36

Capital Expenditure

0.00

-0.01

-0.02

Issuance of Capital Stock

0.00

—

0.15

0.24

—

Issuance of Debt

—

Repayment of Debt

—

Repurchase of Capital Stock

—

Free Cash Flow

0.00

-0.03

-0.04

-0.08

-0.11

Capricor Therapeutics

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL